Carisoprodol Added to Controlled Substance Schedules

Summary#

These final regulations (SOR/2025-222) add Carisoprodol to the federal drug control lists in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act. The instrument was registered on October 30, 2025, published in the Canada Gazette, Part II on November 19, 2025, and comes into force on 2025-12-19.

What it does#

• Adds Carisoprodol to Part 1 of Schedule 1 of the Benzodiazepines and Other Targeted Substances Regulations (listed as item 13).
• Adds Carisoprodol to Schedule 2 of the same Regulations with its chemical name (listed as item 47).
• Sets the rules to take effect on the 30th day after publication (effectively 2025-12-19).

Who's affected#

• People prescribed or using Carisoprodol for medical reasons.
• Doctors, nurse practitioners, and other prescribers who might write prescriptions for the drug.
• Pharmacies, pharmacists, and other dispensers who handle prescriptions.
• Manufacturers, importers, distributors and suppliers of Carisoprodol.
• Law enforcement and health regulators who oversee controlled substances.

Why it matters#

• Putting Carisoprodol on these Schedules means it will be treated as a controlled substance under federal drug control rules.
• That can change how the drug is prescribed, dispensed, imported, sold, stored and tracked.
• In practice, patients and health-care providers may see new paperwork, limits, or monitoring tied to prescriptions and supply.
• The exact operational details and any transition steps are handled by regulators and appear in related guidance and impact analysis documents.